WebJun 8, 2024 · The phase II BRIGHT AML 1003 trial (NCT01546038) aimed to evaluate the effect of using glasdegib, a potent, ... Study design and patient characteristics 1. … WebOct 15, 2024 · Evidence of clinical benefit came from Study BRIGHT AML 1003, a randomized trial comparing glasdegib+LDAC with LDAC alone for treatment of newly …
(PDF) Survival outcomes and clinical benefit in patients with acute ...
WebMay 25, 2024 · 7509 Background: In newly diagnosed AML or high-risk MDS, primary analysis of the randomized phase 2 BRIGHT AML 1003 trial (data cutoff Jan 2024) … WebJan 21, 2024 · Adverse reactions reported in the first 90 days of therapy on the BRIGHT AML 1003 study are shown in Table 3. Table 3: Adverse Reactions Occurring in ≥ 10% of Patients a,b Within the First 90 Days of Therapy in BRIGHT AML 1003. Body System: Adverse Reactions: DAURISMO With Low-Dose Cytarabine N=84: Low-Dose Cytarabine marine corps gunnery sergeant promotion board
Full article: The cost-effectiveness of glasdegib in combination …
WebBRIGHT AML 1003 trial was OS, which was defined as the time from the date of randomization to death from any cause at any time. Secondary objectives included clinical ef-ficacy endpoints, safety and tolerability, pharmacokinetics, and pharmacodynamics. The final study protocol, amend-ments, and informed consent documents were approved WebMar 4, 2024 · The pivotal phase II BRIGHT AML 1003 trial demonstrated a higher complete remission rate (17% vs 2.3%) and significantly longer median overall ... AML in a phase II study . A total of 35 (mostly MDS, 4 with AML) patients (median age 73 years) were included. Stable disease was achieved in 56% of the patients, and 6% had hematological … WebSep 1, 2024 · The BRIGHT AML 1003 randomized phase 2 study (NCT01546038) compared glasdegib (GLAS) plus LDAC vs LDAC-alone in patients with newly diagnosed … marine corps gunnery